Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
DPX-Survivac, a novel T-cell immunotherapy, to induce robust T-cell responses in advanced ovarian cancer Dorigo, O., Fiset, S., MacDonald, L., Bramhecha, Y., Hrytsenko, O., Dirk, B., Rosu, G., Stanford, M. AMER SOC CLINICAL ONCOLOGY. 2020
View details for Web of Science ID 000529994300011